What Is Ozempic? A Plain-English Definition, How It Works, and What It Treats

Key Takeaways

• Ozempic is a once-weekly injectable prescription medication containing semaglutide, a GLP-1 receptor agonist made by Novo Nordisk.
• The FDA has approved it for adults with type 2 diabetes to improve blood sugar control and reduce cardiovascular risk.
• It works by mimicking a gut hormone that signals fullness and slows stomach emptying.
• Semaglutide is the active ingredient in Ozempic.
• It's a synthetic peptide (a small protein) designed to mimic GLP-1, a hormone your gut releases naturally when you eat.

Direct answer (40-60 words)

Ozempic is a once-weekly injectable prescription medication containing semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. The FDA has approved it for adults with type 2 diabetes to improve blood sugar control and reduce cardiovascular risk. It works by mimicking a gut hormone that signals fullness and slows stomach emptying.

Table of contents

1. The 30-second answer
2. The chemistry: what semaglutide actually is
3. What Ozempic is FDA-approved to treat
4. How Ozempic works in your body
5. Ozempic dosing in one paragraph
6. Side effects and warnings
7. How Ozempic differs from Wegovy, Rybelsus, and other GLP-1 drugs
8. Off-label use for weight loss: what to know
9. Cost, insurance, and access
10. Compounded semaglutide: same active ingredient, different product
11. FAQ
12. Footer disclaimers

The chemistry: what semaglutide actually is

Semaglutide is the active ingredient in Ozempic. It's a synthetic peptide (a small protein) designed to mimic GLP-1, a hormone your gut releases naturally when you eat.

Native GLP-1 has a half-life of about 2 minutes. Your body breaks it down quickly via an enzyme called DPP-4. Semaglutide was engineered with three modifications to extend that half-life to about 7 days:

1. A substituted amino acid at position 8 (alpha-aminoisobutyric acid replaces alanine), which makes the peptide resistant to DPP-4 cleavage.
2. A fatty acid chain attached at position 26, which lets the molecule bind reversibly to albumin in the blood. Albumin acts as a slow-release reservoir.
3. An additional amino acid substitution at position 34 to prevent unintended fatty acid binding.

The result is a peptide that activates the same GLP-1 receptors as the natural hormone but lasts a week per dose instead of minutes. That's why Ozempic is dosed weekly rather than several times a day.

What Ozempic is FDA-approved to treat

Ozempic has three FDA-approved indications as of 2026:

1. Type 2 diabetes mellitus. Original approval in December 2017. Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

2. Cardiovascular risk reduction in type 2 diabetes. Approved in January 2020 based on the SUSTAIN-6 trial (Marso et al., New England Journal of Medicine, 2016), which showed semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) by 26% in adults with type 2 diabetes and established cardiovascular disease.

3. Chronic kidney disease in type 2 diabetes. Approved in January 2025 based on the FLOW trial (Perkovic et al., New England Journal of Medicine, 2024), which showed semaglutide reduced major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease.

Ozempic is not FDA-approved for weight loss. The same active ingredient (semaglutide) at a higher dose (2.4 mg weekly) is sold under the brand name Wegovy and is FDA-approved for chronic weight management. Many providers prescribe Ozempic off-label for weight loss in patients without diabetes, but this is an off-label use.

How Ozempic works in your body

GLP-1 receptors are found throughout the body, including in the pancreas, stomach, and brain. When semaglutide activates these receptors, four physiological effects follow:

Effect 1: Glucose-dependent insulin release. The pancreas releases more insulin in response to elevated blood sugar. The "glucose-dependent" part is important: insulin only goes up when blood sugar is high. This is why Ozempic alone rarely causes hypoglycemia (unlike sulfonylureas or insulin itself).

Effect 2: Glucagon suppression. Glucagon is the hormone that tells the liver to release stored sugar. Semaglutide reduces glucagon release after meals, which lowers post-meal blood sugar spikes.

Effect 3: Slowed gastric emptying. Food stays in the stomach longer (about 65% longer at maintenance dose, per Davies et al., Diabetes Care, 2023). This delays the absorption of carbohydrates and increases the duration of fullness after meals.

Effect 4: Central appetite regulation. GLP-1 receptors in the hypothalamus and brainstem regulate hunger signals. Activation reduces appetite and food intake. This is the mechanism behind the weight loss seen in many Ozempic patients.

In type 2 diabetes patients, the typical A1C reduction over 26 to 40 weeks is 1.4 to 1.9 percentage points at therapeutic doses (per the SUSTAIN trial program). Average weight loss is 4 to 6 kg at 1 mg weekly and 6 to 7 kg at 2 mg weekly over the same time period.

Ozempic dosing in one paragraph

Ozempic is dosed once weekly by subcutaneous injection. Patients start at 0.25 mg weekly for 4 weeks (a tolerance dose, not therapeutic), then increase to 0.5 mg weekly. After at least 4 weeks at 0.5 mg, the dose may step up to 1 mg weekly, and after another 4+ weeks, optionally to 2 mg weekly (the maximum approved dose). Each step takes at least 4 weeks. Most patients reach their target dose by week 12 to 16. The pen is injected into the abdomen, thigh, or upper arm, with site rotation each week. For more detail, see our ozempic dosing guide.

Side effects and warnings

The most common side effects of Ozempic, in rough order of frequency in clinical trials:

Most GI side effects are dose-dependent and concentrate in the first 8 to 12 weeks of treatment, with symptoms peaking after each dose escalation and improving over the following 1 to 2 weeks.

Serious but rarer concerns:

• Pancreatitis. Acute pancreatitis is a known risk. Roughly 0.1 to 0.3% of patients in clinical trials. Symptoms: severe upper abdominal pain radiating to the back, persistent vomiting. Stop Ozempic and seek care immediately.
• Gallbladder disease. Rapid weight loss increases gallstone risk. About 1 to 2% of patients in trials had gallbladder events, most often during the highest weight-loss period.
• Diabetic retinopathy worsening. Patients with pre-existing diabetic retinopathy had higher rates of complications in SUSTAIN-6. Mechanism is thought to be rapid glucose normalization, not direct drug toxicity.
• Thyroid C-cell tumors. Black box warning. Animal studies in rats showed thyroid C-cell tumors with semaglutide. Not seen in humans, but Ozempic is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
• Acute kidney injury. Severe vomiting can cause dehydration and pre-renal AKI. Stay hydrated; pause if you can't keep fluids down.

For a deeper look at GI side effects, see our zepbound acid reflux guide (the mechanism is similar across GLP-1 agonists).

How Ozempic differs from Wegovy, Rybelsus, and other GLP-1 drugs

Ozempic, Wegovy, and Rybelsus all contain the same active ingredient (semaglutide) but at different doses and via different delivery routes. Ozempic and Wegovy are functionally similar drugs at different brand names targeted at different FDA indications.

Tirzepatide (Mounjaro and Zepbound) is a different molecule that activates both GLP-1 and GIP receptors. The dual mechanism produces somewhat greater weight loss than semaglutide alone in head-to-head trials (SURMOUNT-1 vs STEP 1).

Off-label use for weight loss: what to know

Ozempic is widely prescribed off-label for weight loss in adults without type 2 diabetes. This practice is legal but has consequences for cost and coverage.

Why providers do it:

• Wegovy (the FDA-approved weight-loss formulation) has been in chronic shortage since 2022.
• Some providers prefer the Ozempic dosing schedule (max 2 mg) over Wegovy's higher target dose (2.4 mg) for patients with mild obesity.
• Some patients have insurance plans that cover Ozempic for diabetes-related criteria but not Wegovy for obesity.

Why it's complicated:

• If your insurance plan checks the diagnosis on the prescription, off-label Ozempic for weight loss is often denied.
• Some plans deny Ozempic prescriptions written for "weight loss" or "obesity" as the primary indication.
• The Novo Nordisk savings card explicitly excludes off-label weight-loss use.

What patients should know:

• A weight-loss prescription for Ozempic isn't medically wrong. The pharmacology supports the use.
• Insurance reimbursement, however, often does not.
• Patients seeking weight loss as the primary goal should discuss whether Wegovy (or compounded semaglutide) is a more appropriate route.

Cost, insurance, and access

With insurance, Ozempic for diabetes: typically $25 to $250 per month after the deductible, depending on formulary tier.

With insurance, Ozempic for weight loss (off-label): often denied. Some plans approve with prior authorization.

Without insurance: Walmart, CVS, and other major pharmacies cash price runs $940 to $1,150 per month. With a GoodRx coupon, $850 to $1,000.

With the Novo Nordisk savings card: as low as $25 per fill for commercial-insured patients with diabetes diagnosis. Card is not valid for Medicare, Medicaid, or off-label weight loss.

Patient Assistance Program (PAP): free Ozempic for low-income patients without commercial coverage who meet eligibility criteria. Income cap is 400% of federal poverty level.

For a deeper breakdown of pricing, see our ozempic cost walmart guide.

Compounded semaglutide: same active ingredient, different product

Compounded semaglutide is sold by 503A and 503B compounding pharmacies. It contains the same chemical entity (semaglutide) when sourced from FDA-registered API suppliers, but the finished product is not the same drug as Ozempic.

Differences:

• Compounded semaglutide is not FDA-approved.
• It's prepared by a state-licensed compounding pharmacy in response to an individual prescription, not mass-manufactured.
• It's drawn from a vial with a U-100 insulin syringe rather than delivered by a pre-filled pen.
• It's typically priced at $179 to $499 per month versus $940+ cash for Ozempic.
• Insurance does not reimburse compounded semaglutide.

When compounded makes sense:

• Insurance doesn't cover Ozempic at an affordable copay
• Patient is uninsured and cash price is unsustainable
• Patient is using semaglutide off-label for weight loss and not eligible for the savings card

When brand-name Ozempic makes more sense:

• Patient has type 2 diabetes and a low-copay insurance plan
• Patient prefers the convenience of a pre-filled pen
• Patient strongly prefers FDA-approved medications

For more on compounded options, see our why compounded semaglutide red guide.

FAQ

What is Ozempic used for? Ozempic is FDA-approved for adults with type 2 diabetes to improve blood sugar control, reduce cardiovascular risk in patients with established cardiovascular disease, and slow the progression of chronic kidney disease. It is widely prescribed off-label for weight loss but is not FDA-approved for that indication.

Is Ozempic the same as Wegovy? Both contain semaglutide, but they are not the same drug. Ozempic is approved for type 2 diabetes at a maximum dose of 2 mg weekly. Wegovy is approved for chronic weight management at a maximum dose of 2.4 mg weekly. Different dosing, different FDA indications, different brand names.

How does Ozempic work? Ozempic is a GLP-1 receptor agonist. It mimics a gut hormone that triggers insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite by acting on the brain's hunger centers. The combined effect lowers blood sugar and supports weight loss.

How is Ozempic taken? Once weekly by subcutaneous injection into the abdomen, thigh, or upper arm. The medication comes in pre-filled pens at four dose strengths (0.25 mg, 0.5 mg, 1 mg, 2 mg). Most patients start at 0.25 mg and titrate up over 12 to 16 weeks.

What are the most common side effects of Ozempic? Nausea (15 to 20%), diarrhea (8 to 9%), vomiting (5 to 9%), and abdominal pain (7 to 8%). Most GI side effects are worst in the first 8 to 12 weeks and improve as the body adapts.

Who shouldn't take Ozempic? Patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2), prior pancreatitis, or known hypersensitivity to semaglutide. Use during pregnancy is not recommended.

Does Ozempic cause weight loss? Yes. Average weight loss in clinical trials was 4 to 6 kg at 1 mg weekly and 6 to 7 kg at 2 mg weekly over 26 to 40 weeks. Weight loss is a consistent secondary effect even when Ozempic is prescribed for diabetes.

Is Ozempic safe long-term? The longest published follow-up is approximately 5 years (continued from SUSTAIN-6 and STEP trials). No new safety signals have emerged. The cardiovascular and kidney benefits suggest sustained Ozempic use is net-beneficial in patients with type 2 diabetes.

How quickly does Ozempic work? Blood sugar effects begin within days. A1C improvements are measurable by 8 to 12 weeks. Weight loss is gradual: typically 2 to 4 lbs in the first month, accelerating to 4 to 8 lbs per month at therapeutic doses.

Can I drink alcohol on Ozempic? Moderate alcohol is not contraindicated. Alcohol can worsen GI side effects and can increase hypoglycemia risk in patients also taking insulin or sulfonylureas. Ozempic alone rarely causes low blood sugar.

Does Ozempic interact with other medications? Ozempic slows gastric emptying, which can affect absorption of oral medications. Most interactions are clinically minor. Patients on warfarin, oral contraceptives, or thyroid medication should mention Ozempic to all prescribers.

Can I stop Ozempic suddenly? You can, but most patients regain a portion of weight lost within 12 months of stopping (per the STEP 4 extension data). For diabetes patients, blood sugar typically rises over weeks to months. Most clinicians prefer a gradual transition rather than abrupt discontinuation.

Is generic Ozempic available? No. Semaglutide is still under patent protection. Generic versions are not expected before 2031 (semaglutide patent expiration) and likely later given Novo Nordisk's strategy to file additional method-of-use patents.

What about compounded semaglutide? Compounded semaglutide is prepared by 503A or 503B pharmacies in response to individual prescriptions. It contains the same chemical entity (semaglutide) but is not FDA-approved and is not interchangeable with Ozempic. Pricing is typically $179 to $499 per month.

Author / review note

Reviewed by the FormBlends Medical Team. References include the Ozempic prescribing information (Novo Nordisk, rev. 2024), Marso et al., New England Journal of Medicine, 2016 (SUSTAIN-6), Perkovic et al., New England Journal of Medicine, 2024 (FLOW), Davies et al., Diabetes Care, 2023 (gastric emptying), and the FDA approval letters for Ozempic (December 2017, January 2020, January 2025).

Sources

1. The Ozempic prescribing information (Novo Nordisk, rev. 2024).
2. Marso et al., New England Journal of Medicine, 2016 (SUSTAIN-6).
3. Perkovic et al., New England Journal of Medicine, 2024 (FLOW).
4. Davies et al., Diabetes Care, 2023 (gastric emptying).
5. The FDA approval letters for Ozempic (December 2017, January 2020, January 2025).

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.